According to Zacks Investment Research, Wall Street stockbrokers expect SQZ Biotechnologies (NYSE:SQZ – Get Rating) to post sales of $7.99 million for the current fiscal quarter. Three analysts have made estimates for SQZ Biotechnologies’ earnings, with the highest estimate of revenue being $10.00 million and the lowest estimate of $4.50 million. The company is expected to release its next quarterly earnings report on Thursday, March 17th.
On average, analysts expect SQZ Biotechnologies to report full-year sales of $22.73 million for the current fiscal year, with estimates ranging from $19.25 million to $24.70 million. For the next fiscal year, analysts expect the company to post revenue of $36.52 million, with estimates ranging from $18.00 million to $59.66 million. Zacks sales averages are averages based on a survey of research firms that follow SQZ Biotechnologies.
Separately, on Sunday, December 12, BTIG Research reiterated a “buy” rating and price target of $40.00 on shares of SQZ Biotechnologies in a research report.
Also on Monday, December 13, Director Amy W. Schulman acquired 3,700 shares of SQZ Biotechnologies in a transaction. The stock was purchased at an average price of $10.91 per share for a total value of $40,367.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC’s website. Company insiders own 18.00% of the Company’s stock.
A number of institutional investors have recently changed their holdings of SQZ. Temasek Holdings Private Ltd increased its position in SQZ Biotechnologies by 8.8% in the third quarter. Temasek Holdings Private Ltd now owns 2,758,169 shares of the company’s shares valued at $39,773,000 after purchasing an additional 223,993 shares last quarter. 683 Capital Management LLC increased its position in SQZ Biotechnologies by 9.4% in the fourth quarter. 683 Capital Management LLC now owns 1,852,135 shares of the company’s stock valued at $16,540,000 after purchasing an additional 159,748 shares last quarter. NanoDimension Inc. acquired a new interest in SQZ Biotechnologies in the fourth quarter for approximately $12,906,000. BlackRock Inc. increased its stake in SQZ Biotechnologies by 13.1% in the fourth quarter. BlackRock Inc. now owns 1,413,870 shares of the company’s stock valued at $12,625,000 after purchasing an additional 163,780 shares last quarter. Finally, Maverick Capital Ltd. increased its stake in SQZ Biotechnologies by 7.5% in the third quarter. Maverick Capital Ltd. now owns 1,056,786 shares of the Company’s shares valued at $15,239,000 after purchasing an additional 73,690 shares last quarter. Institutional investors and hedge funds own 49.07% of the company’s shares.
SQZ stock opened at $5.27 on Tuesday. SQZ Biotechnologies has a 1 year low of $4.64 and a 1 year high of $16.23. The company’s 50-day simple moving average is $7.79.
About SQZ Biotechnologies (get rating)
SQZ Biotechnologies Company, a clinical-stage biotechnology company, is developing transformative cell therapies for patients suffering from cancer, infectious diseases and other serious diseases. Its lead product candidate is SQZ-PBMC-HPV from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical , head and neck, anal, penile, vulva and vaginal cancer.
Get a Free Copy of the Zacks Research Report on SQZ Biotechnologies (SQZ)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was generated by MarketBeat’s narrative science technology and financial data to provide readers with the fastest, most accurate reporting. This story was reviewed by the MarketBeat editorial team before publication. Please send questions or comments about this story to [email protected]
Should You Invest $1,000 in SQZ Biotechnologies Now?
Hear this before you consider SQZ Biotechnologies.
MarketBeat tracks Wall Street’s best-in-class, top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now, before the broader market takes hold… and SQZ Biotechnologies wasn’t on the list.
While SQZ Biotechnologies is currently rated a Buy by analysts, top analysts believe these five stocks are better buys.
Check out the 5 stocks here